Two Sigma Advisers LP Boosts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Two Sigma Advisers LP raised its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1.5% during the 4th quarter, Holdings Channel reports. The fund owned 226,900 shares of the company’s stock after purchasing an additional 3,300 shares during the period. Two Sigma Advisers LP’s holdings in Elanco Animal Health were worth $2,748,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. CoreCap Advisors LLC purchased a new stake in shares of Elanco Animal Health during the 4th quarter worth $29,000. Jones Financial Companies Lllp lifted its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. lifted its position in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after buying an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $61,000. Finally, Blue Trust Inc. grew its position in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after buying an additional 1,894 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Up 4.3%

Elanco Animal Health stock opened at $13.20 on Wednesday. The stock has a 50-day moving average price of $10.43 and a 200 day moving average price of $11.43. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.34 earnings per share. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.89% of the company’s stock.

Analyst Ratings Changes

ELAN has been the subject of several recent analyst reports. UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus raised their price objective on Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, May 19th. Piper Sandler reduced their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Morgan Stanley decreased their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Finally, Barclays dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.